Revolo Biotherapeutics Receives Orphan Drug Designation from the U.S. FDA for its First-in-Class Peptide as a Potential Treatment for Eosinophilic Esophagitis
January 30, 2024 08:30 ET
|
Revolo Biotherapeutics
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
Revolo Biotherapeutics Presents New Data on ‘1805 at the American College of Rheumatology Convergence 2023 Annual Conference
November 07, 2023 10:05 ET
|
Revolo Biotherapeutics
- New preclinical data further elucidate ‘1805’s mechanism of action in rheumatoid arthritis (RA) - NEW ORLEANS and CAMBRIDGE, United Kingdom, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Revolo...
Revolo Biotherapeutics Announces Data from Study of ‘1104 in Atopic Adults
October 25, 2023 08:00 ET
|
Revolo Biotherapeutics
- Treatment with ‘1104 demonstrated a rapid reduction in intradermal allergic inflammation - - Treatment with ‘1104 induced sustained activation of T regulatory and B regulatory cells, providing...
Revolo Biotherapeutics to Present Data from Phase 2a Clinical Trial of ‘1104 in Eosinophilic Esophagitis at ACG 2023
October 17, 2023 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and CAMBRIDGE, United Kingdom, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
Revolo Biotherapeutics Announces the Completion of Phase 1 Multiple Ascending Dose Clinical Trial of ‘1104
September 21, 2023 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and CAMBRIDGE, United Kingdom, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
Revolo Biotherapeutics to Host Virtual KOL Event on ‘1104: A First-in-Class Peptide for Eosinophilic Esophagitis (EoE) and Allergic Disease
August 08, 2023 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and CAMBRIDGE, United Kingdom, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
Revolo Biotherapeutics Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis
July 18, 2023 08:00 ET
|
Revolo Biotherapeutics
- Data shows statistically significant improvement in patient-reported dysphagia symptoms compared to placebo - - Unique broad mechanistic effect across a range of key cell types associated with EoE...
Revolo Biotherapeutics Presents New Data for ‘1805 in Inflammatory Bowel Disease and Rheumatoid Arthritis at the 5th Treg Directed Therapies Summit
June 05, 2023 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and CAMBRIDGE, United Kingdom, June 05, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
Revolo Biotherapeutics Presents New Preclinical Data for ‘1104 in Acute Respiratory Distress Syndrome Associated With Influenza Infection at the ATS 2023 International Conference
May 22, 2023 08:00 ET
|
Revolo Biotherapeutics
Data continues to demonstrate the broader potential of ‘1104 to avoid and reduce inflammation in multiple models of disease, including allergy and beyond NEW ORLEANS and CAMBRIDGE, UK,, May 22, 2023...
Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings
May 10, 2023 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and CAMBRIDGE, United Kingdom, May 10, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve...